Šalis: Malaizija
kalba: anglų
Šaltinis: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
MEFENAMIC ACID
DYNAPHARM (M) SDN BHD
MEFENAMIC ACID
500 Capsule Capsules; 1000 Capsule Capsules
DYNAPHARM (M) SDN BHD
Consumer Medication Information Leaflet (RiMUP) DYFENAMIC TABLET / CAPSULE Mefenamic Acid (250 mg, 500 mg) 1 What is in this leaflet 1. What Dyfenamic is used for 2. How Dyfenamic works 3. Before you use Dyfenamic 4. How to use Dyfenamic 5. While you are using it 6. Side effects 7. Storage and Disposal of Dyfenamic 8. Product Description 9. Manufacturer and Product Registration Holder 10. Date of revision What Dyfenamic is used for Dyfenamic is used to treat mild to moderate pain from various conditions. How Dyfenamic works Mefenamic acid works by reducing the pain and inflammation. Before you use Dyfenamic - When you must not use it Do not use Dyfenamic if you have: • Ulceration or inflammation of gastrointestinal tract. • Allergic to Mefenamic Acid Pregnancy and lactation Do not take Dyfenamic if you are pregnant, trying to get pregnant or think you may be pregnant. Do not take Dyfenamic if you are breast- feeding. Ask your doctor or pharmacist for advice before taking any medicine. - Before you start use it It should be given with care to patients with bleeding disorders, cardiovascular disease, peptic ulceration or a history of such ulceration, and in those who are receiving coumarin anticoagulants. - Taking other medicines Mefenamic Acid may enhance the effects of the coumarin anticoagulants. Tell your doctor if you are taking any other medicines, including any that you buy without a prescription from a pharmacy, supermarket or health food shop. How to use Dyfenamic - How much to use Follow all directions given to you by your doctor and pharmacist carefully. They may differ from the information contained in this leaflet. If you do not understand the instructions on the label, ask your doctor or pharmacist for help. Adults: Pain - 500 mg initially, followed by 250 mg every 6 hours as necessary. Treatment should not be continued for longer than 7 days. Menstrual cramps- Medication should be initiated with the onset of bleeding and associated symptoms and should not be necessary for more than 2 - 3 days. Ch Perskaitykite visą dokumentą
DYFENAMIC DESCRIPTION CONTENT DYFENAMIC CAPSULE 250MG MAL19910013AZ SIN8342P CAPSULE Capsule Colour : Ivory/Blue Capsule Size : # 1 Granules Colour : White To Off-white Each Capsule Contains: Mefenamic Acid ..............250 mg DYFENAMIC TABLET 250MG MAL19910165AZ TABLET Colour : Yellow Shape : Round and Biconvex Coating : Film-coated Each Tablet Contains: Mefenamic Acid ..............250 mg DYFENAMIC TABLET 500MG MAL19910166AZ TABLET Colour : Yellow Shape : Oval, Biconvex and Scored Coating : Film-coated Each Tablet Contains: Mefenamic Acid ..............500 mg PHARMACODYNAMICS: Analgesic action: It may block out pain impulse generation via a peripheral action which may involve inhibition of the synthesis of prostaglandins, and possibly inhibition of the synthesis or action of other substances which sensitise pain receptors to mechanical or chemical stimulation. Anti-inflammatory action: It may act peripherally in inflamed tissue, probably by inhibiting the synthesis of prostaglandins and possibly by inhibiting the synthesis and/or actions of other local mediators of the inflammatory response. PHARMACOKINETICS: Mefenamic Acid is absorbed from the GIT. Peak concentrations on the circulation occur about 2 hours after ingestion. Mefenamic Acid is extensively bound to plasma proteins. Approximately 50% of a dose may be recovered in the urine within 48 hours, mainly as conjugated metabolites. INDICATIONS: Mild to moderate pain such as muscular aches, backaches, dental pain, bursitis, dysmenorrhoea, rheumatic pain, traumatic pain, headaches of most aetiology, postoperative and postpartum pain, rheumatoid arthritis (including Still’s disease) osteoarthritis and menorrhagia due to dysfunctional causes. RECOMMENDED DOSAGE: Adults: Pain - 500 mg initially, followed by 250 mg every 6 hours as necessary. Treatment should not be continued for longer than 7 days. Dysmenorrhoea - Medication should be initiated with the onset of bleeding and associated symptoms and should not be necessary for more than 2 - 3 days. Children wi Perskaitykite visą dokumentą